Core Viewpoint - The company, Brainstorm Aurora-B (06681), has signed significant business cooperation agreements with Peking University Sixth Hospital and Shandong Mental Health Center to advance the research and commercialization of digital therapies for mental health [1][4]. Group 1: Business Developments - The company’s stock price increased by 8.46%, currently trading at 7.82 HKD with a transaction volume of 149 million HKD [1][4]. - The collaboration with Peking University Sixth Hospital and Shandong Mental Health Center aims to enhance the development of mental health digital therapy products [1][4]. - The company has also received approval to establish the "Precision Intelligent Diagnosis and Treatment Innovation and Transformation Key Laboratory for Mental Disorders" in collaboration with Peking University Sixth Hospital and the National Engineering Research Center for Software Engineering [1][4]. Group 2: Strategic Partnerships - The company has formed a close commercial partnership with Beijing Anding Hospital, a top-tier mental health hospital and national center for mental disorders, to promote the clinical application of mental health digital therapy products [1][4]. - The recent partnerships expand the company's network within core mental health specialty hospitals across the country, creating a comprehensive commercial implementation network from national flagship centers to regional hubs and key specialty hospitals [1][4].

Core Viewpoint - The company, Brainstorm Aurora-B (06681), has seen its stock price increase by over 8%, currently trading at 7.75 HKD with a transaction volume of 58.17 million HKD, following the announcement of significant business collaborations aimed at advancing digital therapies for mental health [1] Group 1: Business Collaborations - The company has signed important business cooperation agreements with Peking University Sixth Hospital and Shandong Provincial Mental Health Center to jointly promote the research and commercialization of digital therapy products for mental health [1] - The collaboration with Peking University Sixth Hospital and the National Engineering Research Center for Software Engineering at Peking University has led to the establishment of a key laboratory for precision intelligent diagnosis and treatment of mental disorders in Beijing [1] Group 2: Clinical Applications and Network Expansion - The company has established close commercial cooperation with Beijing Anding Hospital, a top-tier mental health hospital and national center for mental disorders, to promote the clinical application of digital therapy products for mental health [1] - The recent partnerships further expand the company's presence in core mental health specialty hospitals across the country, creating a comprehensive commercial network from national flagship centers to regional hubs and key specialty hospitals [1]

Group 1 - The core viewpoint of the article highlights that Brainstorm Aurora-B (06681) has deposited shares worth HKD 1.959 billion into Guotai Junan (Hong Kong), representing 20.77% of the total shareholding [1] - The company has recently signed significant business cooperation agreements with Peking University Sixth Hospital and Shandong Provincial Mental Health Center to advance the research and commercialization of digital therapies for mental health [1] - Additionally, the joint application for the "Precision Intelligent Diagnosis and Treatment Innovation and Transformation Key Laboratory for Mental Disorders" with Peking University Sixth Hospital and the National Engineering Research Center for Software Engineering has been officially approved for establishment [1]

Core Viewpoint - The company has signed significant business cooperation agreements with Peking University Sixth Hospital and Shandong Provincial Mental Health Center to advance the research and commercialization of digital therapies for mental health [1][4]. Group 1: Collaboration Details - The collaboration with Peking University Sixth Hospital includes the development of digital therapies and clinical application research, focusing on ADHD cognitive digital therapy effectiveness and a precision intelligent diagnosis system for depression [2]. - The research scope encompasses developing digital therapy products for emotional and behavioral issues across the entire lifecycle, including clinical validation of cognitive digital therapies aimed at improving learning abilities in children with ADHD [2]. - The partnership with Shandong Provincial Mental Health Center involves developing cognitive screening and intervention systems for mental disorders, as well as methods for capacity training guided by virtual humans [3]. Group 2: Laboratory Establishment - The "Precision Intelligent Diagnosis and Innovation Transformation Key Laboratory for Mental Diseases" has been officially approved, with the company as a core co-construction unit alongside Peking University Sixth Hospital and the National Engineering Research Center for Software Engineering [3]. - The laboratory will focus on innovation and transformation driven by clinical needs in mental health, integrating clinical medicine, basic research, technology development, and hardware innovation [3]. Group 3: Strategic Positioning - The company has established close commercial cooperation with Beijing Anding Hospital, a top-tier mental health facility, to promote the clinical application of digital mental health therapies [4]. - The recent collaborations expand the company's network across key mental health hospitals in China, creating a comprehensive commercial landing network from national flagship centers to regional hubs and specialized hospitals [4]. - The board believes that the implementation of these cooperation agreements and the approval of the key laboratory will strengthen the company's pioneering advantage in the digital mental health therapy field, accelerating product development and commercialization [4].

转自：北京日报客户端 看病更智能、研发更顺畅、产业更集聚 经过一年发展 AI医汇·朝阳区数字医疗产业生态服务平台 已推动多个重点项目落地 助力区域数字医疗产业高质量发展 一起来看 01 一站式管家服务 硬核成果频出 数字医疗跑出"朝阳速度" 在AI医汇·朝阳区数字医疗产业生态服务平台推动下，一批具有示范意义的合作项目与研究成果加速涌 现。 清华大学医学院、垂杨柳医院、朝阳区疾病预防控制中心与中关村（朝阳）数字医疗产业园共同建设的 转化医学平台，有效促进了数字医疗项目的快速验证与孵化； 中医行业首个数智健康大模型已完成备案申请并正式发布，为中医药数字化转型注入新动力； 中国电信量子科技有限公司与北京玻色量子科技有限公司联合打造的"量子+AI"算力平台，构建起从技 术研发、设备落地到公共服务的完整生态链，为医疗人工智能发展提供底层支撑。 随着"AI医汇"平台的不断完善 破解医疗转型难题 建设AI医汇的初衷，是为辖区数字医疗企业提供从专业技术、运营集成、成果转化等多项服务在内的 全周期、一站式、管家式服务，切实解决传统医疗产业转型中的实际难题。 一年来，中关村朝阳园管委会（区科信局）积极链接优质资源，已形成数字医疗 ...

Group 1 - The core viewpoint of the article highlights that Guorui Life (00108) has seen a significant increase in its stock price, rising over 8% in early trading and currently up by 5.51% to HKD 2.49, with a trading volume of HKD 1.795 million [1] - Guorui Life announced that by December 23, 2025, at least 25% of its issued shares will be held by the public [2] - The company has made a strategic acquisition of approximately 78.3% of the online medical platform "Chunyu Doctor" for about RMB 269 million, which has attracted market attention [2] Group 2 - The acquisition is viewed as a "super entrance" into the digital healthcare sector, providing Guorui Life with a significant opportunity for long-term growth [2] - Chunyu Doctor operates 13 controlled internet hospitals and has established an integrated service loop of "consultation-prescription-medication-management," which is difficult for new entrants to replicate in the short term [2] - The platform possesses a large user base, trusted service qualifications, and substantial data assets, positioning it as a "new infrastructure" in digital healthcare [2]

Group 1 - The core point of the article highlights that Guorui Life (00108) experienced a significant stock price increase, rising over 8% in early trading and currently up by 5.51%, with a trading volume of 1.795 million HKD [1] - On December 23, 2025, Guorui Life announced that at least 25% of its issued shares are held by the public [2] - The company recently announced the acquisition of approximately 78.3% of the online medical platform "Chunyu Doctor" for about 269 million RMB, which has attracted market attention [2] - Industry analysts believe that this acquisition provides Guorui Life with a "super entrance" into the lucrative digital healthcare sector [2] - Chunyu Doctor operates 13 controlled internet hospitals and has established an integrated service loop of "consultation-prescription-medication-management," making it a valuable asset [2] - The large user base and internet hospital qualifications of Chunyu Doctor are considered rare resources that are difficult for new entrants to replicate in the short term [2] - Guorui Life's acquisition is seen as a step towards building a "new infrastructure" in digital healthcare, leveraging vast user trust, complete service qualifications, and substantial data assets [2]

Core Insights - The digital healthcare industry is experiencing robust growth driven by technological innovations and capital investments, particularly in artificial intelligence and brain-computer interface sectors [1][3] Policy Developments - The digital healthcare sector is heavily influenced by government policies, which have been systematically promoting the application and development of emerging technologies like AI and brain-computer interfaces through various measures [3][4] - In 2025, significant policies were introduced to enhance the integration of AI in healthcare, focusing on practical applications and regulatory innovation [3][4] - Brain-computer interfaces have been elevated to a national strategic level, with several milestone policies established to support their development [4][5] Product Innovations - The digital healthcare sector has seen a surge in AI model products, with a notable increase in the number of approved AI medical devices, reaching 207 by December 2025 [11] - AI applications are expanding beyond diagnostic tools to include treatment planning and clinical management, indicating a shift towards integrated healthcare solutions [11][12] - The emergence of specialized AI models for various medical fields, such as oncology and chronic disease management, showcases the sector's innovation and adaptability [8][10] Capital Market Activity - The financing landscape for AI and brain-computer interface sectors has been vibrant, with record-breaking funding rounds, including a notable 1 billion yuan investment in a digital healthcare company [18][19] - The IPO market for AI healthcare companies is gaining momentum, reflecting strong investor interest and the potential for growth in this sector [18][19] Data Utilization - The healthcare industry is advancing towards data assetization, with policies facilitating the efficient sharing and utilization of medical data [15][16] - The second use of medical data is becoming more prevalent, with AI technologies being integrated into various operational and clinical processes [16][17] Market Trends - The focus of digital marketing in healthcare is shifting towards patient-centered services, driven by policy changes and increasing patient awareness [17] - The brain-computer interface sector is witnessing a surge in clinical trials and technological advancements, positioning it as a key area for future growth [14][15]

Core Viewpoint - The company has entered into a strategic cooperation agreement with Natural Health Solutions Programme Group Holdings to promote and expand its digital health products in the Singapore market, addressing the challenges of an aging population and increasing rates of cognitive disorders [1][2]. Group 1: Strategic Cooperation Details - The cooperation includes product promotion, where the company will localize its cognitive disorder digital therapy products for Singapore, while Natural Health Solutions will leverage its offline stores and member resources to recommend the products to target users and provide full-service support [2]. - Market expansion collaboration will involve integrating resources such as products, channels, brands, and technology to jointly develop the Singapore market, focusing on introducing the company's products into leading private and public hospitals [2]. Group 2: Long-term Development Opportunities - The cooperation is expected to deepen the company's international presence and expand into overseas markets, marking the official launch of its Southeast Asia market strategy, building on prior experiences in Hong Kong and Macau [3]. - This partnership is anticipated to enhance the company's brand influence and commercial network in the digital healthcare sector, facilitating quicker product integration into local medical institutions and diversifying into various digital health management markets [3].

Core Viewpoint - The company has entered into a strategic cooperation agreement with Natural Health Solutions Programme Group Holdings to promote digital health products in the Singapore market, addressing the challenges of an aging population and increasing rates of cognitive disorders [1][2]. Group 1: Strategic Cooperation - The agreement focuses on product promotion and market expansion in Singapore, leveraging the local government's initiatives for early screening and health management for cognitive disorders [1]. - The company will localize its cognitive disorder digital therapy products for the Singapore market, while Natural Health Solutions will utilize its network to recommend these products to target users [2]. Group 2: Market Expansion - The collaboration aims to integrate resources such as products, channels, and technology to penetrate the Singapore healthcare system, particularly targeting private and public hospitals [2]. - This partnership marks the company's formal entry into the Southeast Asian market, building on its previous experiences in Hong Kong and Macau [3]. Group 3: Long-term Opportunities - The cooperation is expected to enhance the company's international presence and brand influence, allowing it to export its digital therapy expertise to other supportive regions [3]. - The partnership will strengthen the company's authority and professional image in the digital healthcare sector, facilitating quicker product integration into local medical institutions [3].